Asparkam 175mg+175mg 50 tablets

Correction of K+ and Mg2+ deficiency (as part of combination therapy), including in ischemic heart disease (including acute myocardial infarction), chronic heart failure, arrhythmia (including against the background of cardiac glycoside overdose).

Asparkam is prescribed orally, after meals. It is usually prescribed for adults at a dosage of 1-2 tablets three times a day. The treatment course lasts for 3-4 weeks. If necessary, the course can be repeated.

Composition. 1 tablet contains:
Active ingredients: potassium asparaginate hemihydrate - 0.175 g, magnesium asparaginate tetrahydrate - 0.175 g
Excipients: corn starch - 0.135 g, talc - 0.010 g, calcium stearate - 0.005 g.

Round flat-cylindrical tablets of white or white with a yellowish tint color, with a score line and beveled edges.

Increased sensitivity to the drug, amino acid metabolism disorders, arterial hypotension, acute and chronic renal failure, hyperkalemia, hypermagnesemia, atrioventricular conduction disorders (AV block I-III degree), oliguria, anuria, severe myasthenia, acute metabolic acidosis, amino acid metabolism disorders, dehydration (exsiccosis), hemolysis, Addison's disease.
With caution:
Hypophosphatemia, urolithiasis (associated with calcium, magnesium, and ammonium phosphate metabolism disorders), pregnancy (especially the first trimester) and lactation period.
Pregnancy and lactation:
With caution.

Regular monitoring of electrolyte homeostasis is necessary.

Possible side effects include nausea, vomiting, diarrhea, epigastric pain (in patients with achlorhydric gastritis or cholecystitis), hyperkalemia (nausea, vomiting, diarrhea, paresthesia), and hypermagnesemia (facial flushing, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, seizures).

Symptoms: hyperkalemia and hypermagnesemia.
Treatment: intravenous calcium chloride; if necessary - hemodialysis and peritoneal dialysis.

Pharmacodynamics: Concurrent use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, ACE inhibitors, and non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia, potentially leading to arrhythmias and asystole. The use of potassium preparations together with glucocorticoids eliminates hypokalemia caused by the latter. Under the influence of potassium, the undesirable effects of cardiac glycosides are reduced. Magnesium decreases the effect of neomycin, polymyxin B, tetracycline, and streptomycin. Anesthetics enhance the depressant effect of magnesium preparations on the central nervous system; simultaneous use with atracurium, decamethonium, succinylcholine, and suxamethonium may intensify neuromuscular blockade; calcitriol increases magnesium levels in plasma, while calcium preparations reduce the effect of magnesium preparations.
Enhances the negative dromo- and batmotropic effects of antiarrhythmic agents.
Pharmacokinetics: Astringents and coating agents reduce the absorption of the drug in the gastrointestinal tract.

Asparcam is a source of potassium and magnesium ions, regulating metabolic processes. The mechanism of action is presumably related to the role of potassium and magnesium aspartate as a carrier of magnesium and potassium ions into the intracellular space and its involvement in metabolic processes. Thus, Asparcam eliminates electrolyte imbalance, reduces excitability and conductivity of the myocardium (moderate antiarrhythmic effect).

Easily absorbed when taken orally and relatively quickly excreted by the kidneys.